We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+1.9%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$3.17B
AUM Growth
+$561M
Cap. Flow
+$1.16B
Cap. Flow %
36.62%
Top 10 Hldgs %
63.1%
Holding
323
New
68
Increased
74
Reduced
74
Closed
84

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$37.9M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$24.5M
3
MRK icon
Merck
MRK
+$12.3M
4
GILD icon
Gilead Sciences
GILD
+$11.7M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$11.6M

Top Sells

Rank Stock Value
1
ACHC icon
Acadia Healthcare
ACHC
+$16.4M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$9.99M
3
TSLA icon
Tesla
TSLA
+$7.93M
4
LRMR icon
Larimar Therapeutics
LRMR
+$4.64M
5
OCUL icon
Ocular Therapeutix
OCUL
+$3.33M

Sector Composition

Rank Sector Weight
1 Miscellaneous 89.52%
2 Healthcare 9.63%
3 Energy 0.42%
4 Industrials 0.14%
5 Consumer Staples 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
251
PUT
Exelixis
EXEL
$14.1B
– –
-2,864
Closed -$438K
EYPT icon
252
CALL
EyePoint Inc
EYPT
$316M
– –
-35
Closed -$155K
EYPT icon
253
EyePoint Inc
EYPT
$316M
– –
-8,908
Closed -$394K
EYPT icon
254
PUT
EyePoint Inc
EYPT
$316M
– –
-89
Closed -$393K
GERN icon
255
CALL
Geron
GERN
$842M
– –
-4,859
Closed -$2.45M
GERN icon
256
PUT
Geron
GERN
$842M
– –
-107
Closed -$65K
INCY icon
257
CALL
Incyte
INCY
$24.7B
– –
-431
Closed -$2.11M
INSM icon
258
Insmed
INSM
$26.2B
– –
-10,000
Closed -$142K
IRWD icon
259
CALL
Ironwood Pharmaceuticals
IRWD
$671M
– –
-170
Closed -$464K
LSTA icon
260
CALL
Lisata Therapeutics
LSTA
$13.9M
– –
-2
Closed -$192K
LSTA icon
261
Lisata Therapeutics
LSTA
$13.9M
– –
-76
Closed -$63K
LSTA icon
262
PUT
Lisata Therapeutics
LSTA
$13.9M
– –
-2
Closed -$145K
PBYI icon
263
CALL
Puma Biotechnology
PBYI
$477M
– –
-358
Closed -$8.54M
PGEN icon
264
Precigen
PGEN
$2.51B
– –
-26,507
Closed -$581K
PLUR icon
265
Pluri
PLUR
$14.4M
– –
-1,488
Closed -$323K
QURE icon
266
uniQure
QURE
$2.99B
– –
-67,313
Closed -$620K
SRPT icon
267
PUT
Sarepta Therapeutics
SRPT
$2.19B
– –
-423
Closed -$893K
TNXP icon
268
CALL
Tonix Pharmaceuticals
TNXP
$199M
– –
0
– -$171K
TNXP icon
269
Tonix Pharmaceuticals
TNXP
$199M
– –
0
– -$345K
TNXP icon
270
PUT
Tonix Pharmaceuticals
TNXP
$199M
– –
0
– -$708K
TSLA icon
271
Tesla
TSLA
$1.41T
– –
-489,945
Closed -$7.93M
TSLA icon
272
PUT
Tesla
TSLA
$1.41T
– –
-17,415
Closed -$28.2M
TVTX icon
273
CALL
Travere Therapeutics
TVTX
$5.89B
– –
-1,710
Closed -$1.54M
VCEL icon
274
Vericel Corp
VCEL
$2.03B
– –
-876,173
Closed -$2.5M
VNDA icon
275
Vanda Pharmaceuticals
VNDA
$302M
– –
-81,600
Closed -$966K
9 10
11
12 13

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sabby Management held 323 positions worth $3.17B, up 22% from $2.6B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $1.16B of net new capital in Q4 2014, opening 68 new positions and adding to 74 existing holdings. Its largest new stake was Pfizer: 1,322,658 shares worth $39.1M.

By sector, the portfolio is most concentrated in Miscellaneous at 90% of assets, down from 92% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was Larimar Therapeutics, an estimated $4.64M trimmed.

  • Sabby Management's largest Q4 2014 buy was Pfizer: 1,322,658 shares worth $39.1M.
  • Sabby Management added most to Achillion Pharmaceuticals in Q4 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q4 2014 reduction was Larimar Therapeutics, cutting an estimated $4.64M.
  • Sabby Management fully exited Acadia Healthcare in Q4 2014, selling an estimated $16.4M.
  • Sabby Management's ten largest holdings make up 63% of its $3.17B portfolio in Q4 2014.
  • Sabby Management opened 68 new positions and closed 84 in Q4 2014.
  • Sabby Management's portfolio value rose 22% quarter-over-quarter to $3.17B.

Based on Sabby Management's 13F filing for Q4 2014, filed 17 Feb 2015.